Themis Bioscience Publishes Compelling Phase 2 Results for Lead Vaccine Candidate against Chikungunya Fever in The Lancet

Themis Bioscience Announces Exclusive Licensing Agreement with Max- Planck-Innovation to Develop and Commercialize Oncolytic Virotherapies